AVS Completes a $36M Series B Financing Ahead of IVL U.S. Commercial Launch
Summary
BOSTON, January 28, 2025--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL platform, announced today that it has completed a Series B round of financing of $36M. The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the companys Pulse Intravascular Lithotripsy (PIVL) device. "AVS is the second company to conduct a peripheral intravascular lithotripsy pivotal IDE trial in the U.S. By introducing a new, innovative treatment for calcified arterial disease, we can make a dramatic impact on patient lives and improve outcomes," said Dr. Chris Metzger, National Principal Investigator of the POWER PAD II Study and Interventional Cardiologist at OhioHealth Riverside Methodist Hospital.The funding will also support the companys coronary U.S. IDE study. "Because the Pulse IVL device uses a unique mechanism of action that eliminates the need for electrical emitters, the deliverability, crossability and efficiency are optimized for very challenging and tortuous coronary cases," said Steven Yakubov, Medical Director of the OhioHealth Research Foundation, Columbus, OH and member of AVS Physician Steering Committee.Lastly, the capital raised will support the U.S. carotid IDE trial, as part of its partnership with the Jacobs Institute in Buffalo, NY, led by Dr. Adnan Siddiqui. Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease.